Chemoimmunotherapy of stage III breast carcinoma with BCG and a live allogeneic tumor cell vaccine

Daria H. Pardridge, F. C. Sparks, James E Goodnight Jr, Irene K. Spears, D. L. Morton

Research output: Contribution to journalArticlepeer-review


Ten women with metastatic breast carcinoma were treated with CMF, BCG, and a live TCV in a phase I study to determine whether viable allogeneic tumor cells can safely be given to women receiving adjuvant chemotherapy. Side effects of fatigue, nausea, vomiting, alopecia, and myelosuppression were attributable to chemotherapy. Side effects of BCG therapy were malaise, fever, and pruritis at the injection site, as previously described. Four patients developed hepatitis B due to viral contamination of the human agamma serum in which the tumor cells were grown. This complication has now been eliminated by omitting human sera, and hence the possibility of hepatitis B virus, from tumor cell growth media. No local tumor growth was observed in any patient. Results of this study show that live TCV is safe for patients receiving chemotherapy, and could be tested in combination with BCG and chemotherapy for control of micrometastases from breast cancer following mastectomy.

Original languageEnglish (US)
Pages (from-to)217-220
Number of pages4
JournalCancer Immunology and Immunotherapy
Issue number4
StatePublished - Feb 1979

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research


Dive into the research topics of 'Chemoimmunotherapy of stage III breast carcinoma with BCG and a live allogeneic tumor cell vaccine'. Together they form a unique fingerprint.

Cite this